Core Viewpoint - The company is planning to acquire assets through the issuance of shares and/or cash payments, leading to a temporary suspension of its stock trading due to uncertainties surrounding the transaction [1] Group 1 - The stock will be suspended from trading starting September 8, 2025, and the suspension is expected to last no more than 10 trading days [1] - The company and relevant parties are actively advancing the transaction and are in discussions to confirm the transaction plan [1]

截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 证券代码：300111 证券简称：向日葵 公告编号：2025—036 浙江向日葵大健康科技股份有限公司 关于股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 浙江向日葵大健康科技股份有限公司（以下简称"公司"）于近日接到股东 吴建龙先生的通知，获悉吴建龙先生将其所持有的公司部分股份办理了解除质押 业务，具体事项如下： 二、股东股份累计质押基本情况 四、备查文件 1、解除证券质押登记通知； 2、中国证券登记结算有限责任公司证券质押及司法冻结明细表。 特此公告。 浙江向日葵大健康科技股份有限公司董事会 | | | | | | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 持股数量 （股） | 持股 比例 | 累计被质 押数量 | 占其 所持 股份 | 占公 司总 股本 | 已质押股 份限售和 | 占已 | 未质押股 | 占未 质押 ...

证券代码：300111 证券简称：向日葵 公告编号：2025—037 公司所有信息均以在指定信息披露媒体披露的内容为准。公司本次筹划的交 易事项尚存在较大不确定性，敬请广大投资者注意投资风险。 特此公告。 浙江向日葵大健康科技股份有限公司董事会 2025 年 9 月 12 日 浙江向日葵大健康科技股份有限公司（以下简称"公司"）正在筹划以发行 股份及/或支付现金的方式购买资产事项（以下简称"本次交易"）。因有关事 项尚存不确定性，为了维护投资者利益，避免对公司证券交易造成重大影响，根 据深圳证券交易所的相关规定，经公司申请，公司股票（证券简称：向日葵，证 券代码：300111）自 2025 年 9 月 8 日开市时起开始停牌，停牌时间预计不超过 10 个 交 易 日 。 具 体 内 容 详 见 公 司 于 2025 年 9 月 8 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《关于筹划重大资产重组的停牌公告》（公 告编号：2025-034）。 截至本公告披露日，公司及有关各方正在积极推进本次交易的相关工作，相 关各方正在就交易方案进行协商、论证和确认。为维护投资者利 ...

Group 1: Mergers and Acquisitions Overview - During the period from September 5 to September 11, 2025, two listed companies announced new mergers and acquisitions, namely *ST Bosen and Xiangrikui, involving two merger and acquisition events in the textile and apparel, and pharmaceutical industries [1][7]. Group 2: *ST Bosen - *ST Bosen is focused on men's apparel design, production, and sales, with its main brand "Bosen Men's Wear" promoting the concept of "comfortable business men's clothing" [2][7]. - The company plans to sell 35% of its stake in Shaanxi Bosen Apparel Intelligent Manufacturing Co., Ltd. to Nantong Erfangji Co., Ltd. in cash, aiming to optimize its asset structure and improve cash flow [2][7]. - Shaanxi Bosen was established on April 13, 2021, with a registered capital of 200 million yuan, and is primarily engaged in clothing manufacturing and sales [2][7]. Group 3: Xiangrikui - Xiangrikui is engaged in the research, production, and sales of pharmaceuticals, focusing on anti-infection, cardiovascular, and digestive system drugs, with a complete integrated industrial chain [3][8]. - The company plans to acquire a controlling stake in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through issuing shares and/or cash payments, while also raising matching funds [3][8]. - Major products include clarithromycin raw materials and tablets, widely used for treating infectious diseases, hypertension, and digestive system diseases [3][8].

第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300111 证券简称：向日葵 公告编号：2025—035 浙江向日葵大健康科技股份有限公司 浙江向日葵大健康科技股份有限公司（以下简称"公司"）第六届董事会第 八次会议通知于 2025 年 9 月 9 日以口头、邮件的方式发出，经全体董事同意豁 免会议通知时间要求。会议于 2025 年 9 月 10 日上午 10:00 在公司会议室以现场 与通讯相结合的方式召开，会议由董事长吴少钦先生主持，本次会议应出席董事 7 人，实际出席董事 6 人（潘卫标先生因个人身体原因缺席本次会议），公司监 事和高级管理人员列席了本次会议。会议的召集和召开符合《公司法》和《公司 章程》的有关规定。 经与会董事认真审议，形成如下决议： 一、审议通过《关于公司支付意向金的议案》 公司正在筹划以发行股份及/或支付现金的方式收购漳州兮璞材料科技有限 公司（以下简称"兮璞材料"）的控股权及浙江贝得药业有限公司 40%股权。 公司与标的公司兮璞材料主要股东上海兮噗科技有限公司签署了《浙江向日 葵大健康科 ...

Core Viewpoint - The company, Sunflower (300111.SZ), announced a significant asset restructuring plan involving the acquisition of controlling stakes in two companies, which led to a notable increase in its stock price prior to the announcement [1][4]. Group 1: Acquisition Details - Sunflower plans to acquire a controlling stake in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through a combination of share issuance and/or cash payment [1][4]. - The transaction is still in the planning stage, and the valuations of the target companies have not been finalized [4]. - The acquisition of Beid Pharmaceutical, if successful, would make it a wholly-owned subsidiary of Sunflower [8][6]. Group 2: Financial Performance - Sunflower's financial performance has been under pressure, with a reported revenue of 144 million yuan in the first half of 2025, a year-on-year decrease of 8.33%, and a net profit of only 1.16 million yuan, down 35.68% [2][11]. - The company has experienced declining revenues and profits since its peak in 2010, with significant fluctuations in net profit over the years [10][11]. Group 3: Market Reaction and Uncertainties - Prior to the announcement, Sunflower's stock price surged by over 14% on September 5, 2025, before closing with an 11.96% increase [2][8]. - There are market concerns regarding the feasibility of the acquisitions, especially given Sunflower's history of unsuccessful cross-industry ventures [3][9].

Core Viewpoint - The company Sunflower (300111.SZ) announced a significant asset restructuring plan involving the acquisition of controlling stakes in two companies, which has led to a notable increase in its stock price prior to the announcement [1][4]. Group 1: Acquisition Details - Sunflower plans to acquire the controlling stake in Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. [1][4] - The company intends to raise matching funds for this acquisition, which is expected to constitute a major asset restructuring [4][5]. - The acquisition is still in the planning stage, and the valuations of the target companies have not been finalized [4][5]. Group 2: Stock Performance - On September 5, the trading day before the announcement, Sunflower's stock price surged by over 14%, closing with an increase of 11.96% [2][8]. - The stock was suspended from trading starting September 8 to ensure fair information disclosure and avoid abnormal price fluctuations [5]. Group 3: Financial Performance - Sunflower's financial performance has been under pressure, with a reported revenue of 144 million yuan in the first half of 2025, a year-on-year decrease of 8.33%, and a net profit of 1.16 million yuan, down 35.68% [2][11]. - The company has experienced declining revenues and profits since its peak in 2010, with significant fluctuations in financial performance over the years [10][11]. Group 4: Strategic Direction - Sunflower has previously indicated a desire to seek opportunities for external growth through various means [3]. - The current acquisition represents a cross-industry move into the semiconductor materials sector, which raises questions about the company's ability to successfully navigate this transition [3][12].

图 向日葵曾在光伏领域深耕多年，自2019年主导医药转型后，实控人吴建龙频繁推动跨界投资，致使公司 业务重心趋于分散。细数其来时路，多少带点"追热点"的投机属性——很难说是基于长期产业逻辑进行 的战略布局，更像是对行业周期红利的短期追逐。 2019年6月，向日葵以3.55亿元现金收购贝得药业60%股权，跨界切入当时大热的医药赛道；又在同年 12月通过资产重组出售向日光电100%股权及聚辉新能源100%股权，剥离原有亏损的光伏相关业务，完 成从光伏向医药大健康行业的切换，聚焦抗感染、抗高血压等药物的研发、生产和销售。 片由AI生成 一家在光伏、医药之间来回摇摆的老将，如今再次试图借半导体材料突围。 9月7日晚间，深交所创业板公司向日葵公告显示，正在筹划以发行股份及/或支付现金的方式收购半导 体材料公司兮璞材料控股权，以及控股子公司贝得药业剩余40%股权。交易预计构成重大资产重组但不 改变实控人，股票自9月8日起停牌，10个交易日内将披露完整方案。 停牌前最后一个交易日（9月5日），向日葵股价已提前躁动，截至当日收盘涨幅达11.96%，总市值攀 升至64亿元；8月29日公司股价也曾异动，当日收涨15.83%，同样 ...

9月7日晚，向日葵（SZ300111，停牌）公告，公司正在筹划以发行股份及（或）支付现金的方式收购 漳州兮璞材料科技有限公司（以下简称兮璞材料）的控股权及浙江贝得药业有限公司（以下简称贝得药 业）40%股权，同时拟募集配套资金。本次交易尚处于筹划阶段，截至本公告披露日，兮璞材料及贝得 药业的估值尚未最终确定。经初步测算，本次交易预计构成《上市公司重大资产重组管理办法》规定的 重大资产重组。本次交易不会导致公司实际控制人发生变更，不构成重组上市。经公司申请，公司股票 2025年9月8日（星期一）上午开市起停牌。公司预计在不超过10个交易日的时间内披露本次交易方案。 公开资料显示，兮璞材料是一家半导体市场电子材料供应商，致力于开发半导体市场的先进材料。如果 收购成功，向日葵将由一家化学制药企业跨界进入半导体领域，开辟一条新的赛道。 从交易框架来看，向日葵此次收购涉及两家标的公司，且已与核心交易对方签署意向协议，交易细节与 合规属性已初步明确。 对于贝得药业，公告显示其目前已是向日葵的控股子公司。天眼查信息显示，向日葵持有贝得药业60% 股权，剩余40%股权由绍兴向日葵投资有限公司（以下简称绍兴向日葵）持有。此次交 ...

Core Viewpoint - Company Sunflower (300111.SZ) plans to diversify by acquiring a semiconductor electronic specialty gas company, indicating a strategic shift to enhance growth opportunities amid declining performance in its core pharmaceutical business [1][2]. Company Summary - Sunflower is planning to acquire a controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment, while also raising matching funds [1]. - The company specializes in anti-infection, cardiovascular, and digestive system drugs, and has established an integrated business model involving pharmaceutical intermediates and finished products [1]. - In April 2024, Sunflower reported a revenue of 330 million yuan, a year-on-year decrease of 2.38%, with a net profit of 6.26 million yuan, marking a return to profitability [2]. Industry Summary - The semiconductor electronic specialty gas market is experiencing significant growth, driven by the rise of the semiconductor and new energy sectors, with the market size expected to grow from 22.08 billion yuan in 2022 to 31.66 billion yuan by 2025, reflecting a compound annual growth rate of 12.8% [3]. - The demand for electronic gases is increasing due to tightening export controls in the overseas semiconductor industry, necessitating enhanced domestic production capabilities [3]. - Current market focus is on companies specializing in the research and production of electronic specialty gases, while the importance of companies with a solid industrial gas base is often overlooked [3].